Heartflow Plaque Analysis Now Covered by Aetna Insurance Plans Nationwide and for the Majority of Insured Lives in the U.S.

Core Insights - Heartflow, Inc. has received comprehensive coverage for its AI-powered Heartflow Plaque Analysis from Aetna, marking a significant milestone in expanding access to this technology for coronary artery disease [1][3] - Aetna is the fourth major national commercial insurer to provide this coverage, following similar decisions by Humana, Cigna, and UnitedHealthcare, which enhances the accessibility of Heartflow Plaque Analysis across the United States [1][3] - The new Category I CPT payment code 75577 for Heartflow Plaque Analysis, effective January 1, 2026, establishes a reimbursement structure that supports the financial viability of this service [2][4] Coverage and Policy Changes - Aetna's updated policy became effective on December 23, 2025, allowing coverage for patients with acute or stable chest pain and mild-to-moderate coronary artery narrowing [3] - The policy aims to facilitate earlier diagnosis and personalized management of coronary artery disease through AI-driven plaque analysis [3][4] Clinical Validation and Impact - The DECIDE Registry data indicates that over 50% of patients had their medical management altered when Heartflow Plaque Analysis was utilized, demonstrating its clinical impact [5] - Heartflow Plaque Analysis has been validated through over 100 studies involving more than 365,000 patients, showcasing its effectiveness in real-world clinical practice [7][8] Technological Advancements - Heartflow's technology is the only FDA-cleared AI-powered plaque quantification tool, achieving 95% agreement with the gold standard, IVUS [6] - The platform utilizes a proprietary data pipeline built from over 160 million annotated CTA images, enhancing the accuracy and reproducibility of insights [7] Market Presence and Adoption - Heartflow has been adopted by more than 1,400 institutions globally, indicating a strong commercial presence and commitment to expanding access to its innovative solutions [7] - The company aims to redefine cardiovascular care by transforming coronary artery disease management through early detection and personalized treatment strategies [9]